Dr Jovan P. Antović MD, PhD is an associate professor and senior lecturer in coagulation & clinical chemistry and responsible for clinical chemistry part on the course Human Disease - 2 of MD programme at Karolinska Institutet, Stockholm Sweden. On the clinical part he is a senior consultant, medical head of coagulation diagnostics at Clinical Chemistry, Karolinska University Hospital, Stockholm, Sweden. He is also a visiting professor in hematology at Faculty of Medicine Nis and Faculty of Medicine Kragujevac in Serbia. He is a member of EQUALIS (Swedish external quality assessment for clinical laboratory investigations) expert group in coagulation.
He received his MD degree in 1993 and specialist degree in Internal Medicine - Hematology in 1998 at Faculty of Medicine, University of Nis, Serbia working at Department of Hematology, Clinical Centre Nis. After short stay in Centre for Thrombosis and Hemostasis at University of Chapel Hill, NC, USA he has worked at Karolinska University Hospital and Institutet since 2000, excepting 20 months period (July 2004-March 2006) when he worked as International Medical Advisor in Novo Nordisk. At Karolinska he also received specialist degree in Clinical Chemistry in 2011.
He participates in several national and international projects in the field of both thrombosis and bleeding and leads a project about global hemostatic assays in hemophilia. Apart that, his area of interests are microparticles and cross-talk between coagulation and inflammation as well as laboratory diagnosis of heparin induced thrombocytopenia and markers of thrombin generation. Recently he has also been focused on laboratory methods for follow up of direct oral anticoagulants.
He was a main tutor to one and co-tutor for three graduated PhD students and is currently a tutor to two PhD students and tutor to three post-doc engaged on projects about global hemostatic assays both in hemophilia and thrombophilia and thrombosis.
He is author or co-author in more than 50 articles published in peer-review journals and co-editor of guide textbook Essential guide to coagulation (two editions) and a member of Editorial Board of J Thromb Haemost.
Evaluation of small-volume tubes for venous and capillary PT (INR) samples
International journal of laboratory hematology 2015;37(5):699-704
Improvement of fibrin clot structure after factor VIII injection in haemophilia A patients treated on demand
Thrombosis and haemostasis 2014;111(4):656-61
On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation
Thrombosis research 2014;134(4):783-9
Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma
European journal of clinical pharmacology 2013;69(11):1875-81
Is a decrease of microparticles related to improvement of hemostasis after FVIII injection in hemophilia A patients treated on demand?
Journal of thrombosis and haemostasis : JTH 2013;11(4):697-703
Obesity and thrombin-generation profiles in women with venous thromboembolism
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2013;24(5):547-53
Pneumatic tube transport affects platelet function measured by multiplate electrode aggregometry
Thrombosis research 2013;132(1):77-80
The evaluation of two automated soluble fibrin assays for use in the routine hospital laboratory
International journal of laboratory hematology 2013;35(6):666-71
Thrombin generation in acute cardioembolic and non-cardioembolic ischemic stroke
Scandinavian journal of clinical and laboratory investigation 2013;73(7):576-84
Comparison of five point-of-care D-dimer assays with the standard laboratory method
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY 2012;34(5):495-501
On-demand but not prophylactic treatment with FVIII concentrate increase thrombin activatable fibrinolysis inhibitor activation in severe haemophilia A patients
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY 2012;34(1):35-40
Release of endothelial microparticles in vivo during atorvastatin treatment; a randomized double-blind placebo-controlled study
THROMBOSIS RESEARCH 2012;129(1):95-7
Two global haemostatic assays as additional tools to monitor treatment in cases of haemophilia A
THROMBOSIS AND HAEMOSTASIS 2012;108(1):21-31
Associations between anemia and coagulation abnormalities in women with menorrhagia
THROMBOSIS RESEARCH 2011;:S142-S142
Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease
THROMBOSIS AND HAEMOSTASIS 2011;106(2):344-52
High BMI is correlated to increased thrombin generation in women, age 18-65 after venous thromboembolism
THROMBOSIS RESEARCH 2011;:S140-S140
Inflammatory and haemostatic markers in idiopathic intracranial hypertension
JOURNAL OF INTERNAL MEDICINE 2011;270(5):496-9
Practical Viewpoints on the Diagnosis and Management of Heparin-Induced Thrombocytopenia
SEMINARS IN THROMBOSIS AND HEMOSTASIS 2011;37(3):328-36
Two global haemostatic assays as additional tools to monitor treatment in cases of haemophilia A
A multicolor flow cytometric assay for measurement of platelet-derived microparticles
THROMBOSIS RESEARCH 2010;125(3):e110-6
Changes in Platelets and Anticoagulant Protein Activity During Adenosine-Exercise Single-Photon Emission Computed Tomography Stress Test
SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO 2010;:28-32
Could global hemostatic methods (ETP and OHP) be instrumental in the individualization of patients and tailoring treatment of hemophilia A?
Could rapid particle gel immunoassay (ID-PaGIA) replace standard ELISA for laboratory detection of heparin/pf4 antibodies?
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY 2010;32(4):454-7
"POINT-OF-CARE" D-DIMER TESTING
JOURNAL OF MEDICAL BIOCHEMISTRY 2010;29(4):282-287
Coagulation abnormalities in women with menorrhagia
THROMBOSIS RESEARCH 2009;:S132-S132
Elevations in soluble CD40 ligand in patients with high platelet aggregability undergoing percutaneous coronary intervention
BLOOD COAGULATION & FIBRINOLYSIS 2009;20(4):283-9
Factor XI deficiency in animal models
JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2009;:79-83
Inflammation and thrombin generation cause increased thrombin activatable fibrinolysis inhibitor levels in experimental human endotoxemia
BLOOD COAGULATION & FIBRINOLYSIS 2009;20(7):611-3
Coagulation abnormalities associated with severe isolated traumatic brain injury: Cerebral arterio-venous differences in coagulation and inflammatory markers
JOURNAL OF NEUROTRAUMA 2007;24(1):174-80
Comparison of two immunochemical assays for measuring thrombin-activatable fibrinolysis inhibitor concentration with a functional assay in patients with acute coronary syndrome
THROMBOSIS RESEARCH 2007;121(2):175-81
High incidence of coagulation disorders may justify the routine coagulation screening in women with menorrhagia
THROMBOSIS RESEARCH 2007;:S117-S118
Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke
BLOOD COAGULATION & FIBRINOLYSIS 2007;18(4):365-70
Hemostatic and inflammatory disturbances are present in patients with ischemic stroke
Thrombin activatable fibrinolysis inhibitor antigen could not be detected in cerebrospinal fluid
THROMBOSIS AND HAEMOSTASIS 2005;93(1):178-9
Antithrombin antigen and activity in patients with acquired antithrombin deficiency - is there a difference?
JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2004;2(5):838-9
Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION 2004;64(8):745-51
Overall hemostatic potential (OHP) assay - a possible tool for determination of prothrombotic pattern in FXII deficiency
JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2004;2(11):2058-60
Does recombinant factor VIIa, apart from overall hemostasis, regulate TAFI dependent fibrinolysis in factor VIII deficient plasma and in hemophilia a patients?
Does recombinant factor Vlla, apart from overall hemostasis, regulate TAFI dependent fibrinolysis? In vitro analysis using overall hemostasis potential (OHP) assay
THROMBOSIS AND HAEMOSTASIS 2003;90(4):620-7
Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications
BLOOD COAGULATION & FIBRINOLYSIS 2003;14(6):551-6
Thrombin activatable fibrinolysis inhibitor (TAFI). A link between coagulation and fibrinolysis
Clinical laboratory 2003;49(9-10):475-86
Blood coagulation and fibrinolysis in acute ischaemic and haemorrhagic (intracerebral and subarachnoid haemorrhage) stroke: does decreased plasmin inhibitor indicate increased fibrinolysis in subarachnoid haemorrhage compared to other types of stroke?
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION 2002;62(3):195-9
Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation?
THROMBOSIS AND HAEMOSTASIS 2002;88(4):644-7
Elevated TAFIa/ai antigen levels are a marker for hyperfibrinolytic state in hemophilia patients.
Overall haemostatic potential can be used for estimation of thrombin-activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to factor VIII
Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation
THROMBOSIS RESEARCH 2002;106(1):59-62
Activation of the coagulation system occurs within rather than outside cutaneous haemangiomas
ACTA PAEDIATRICA 2001;90(10):1137-40
Evaluation of a new immunoturbidimetric test (Liatest (R) antithrombin III) for determination of antithrombin antigen
CLINICAL AND LABORATORY HAEMATOLOGY 2001;23(5):313-6
Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A